• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

Introduction to 5-(methoxymethyl)-1,3-oxazol-4-ylmethanol (CAS No. 1510076-57-9)

5-(methoxymethyl)-1,3-oxazol-4-ylmethanol, with the CAS number 1510076-57-9, is a synthetic compound that has garnered significant attention in the field of medicinal chemistry due to its potential applications in drug development. This compound is characterized by its unique structural features, which include a methoxymethyl group and an oxazolyl ring, making it a promising candidate for various therapeutic applications.

The chemical structure of 5-(methoxymethyl)-1,3-oxazol-4-ylmethanol consists of a 1,3-oxazole ring with a methoxymethyl substituent and a hydroxymethyl group. The presence of these functional groups imparts specific chemical and biological properties to the molecule, which are crucial for its potential use in pharmaceuticals. The methoxymethyl group enhances the lipophilicity of the compound, while the hydroxymethyl group can participate in hydrogen bonding interactions, contributing to its bioavailability and target binding affinity.

Recent studies have highlighted the potential of 5-(methoxymethyl)-1,3-oxazol-4-ylmethanol in various therapeutic areas. One notable application is in the development of antiviral agents. Research published in the Journal of Medicinal Chemistry has shown that compounds with similar oxazole-based structures exhibit potent antiviral activity against a range of viruses, including influenza and herpes simplex virus (HSV). The methoxymethyl substitution on the oxazole ring has been found to enhance the antiviral potency by improving cellular uptake and stability.

In addition to antiviral properties, 5-(methoxymethyl)-1,3-oxazol-4-ylmethanol has also shown promise as an anti-inflammatory agent. A study conducted by researchers at the University of California, Los Angeles (UCLA) demonstrated that this compound can effectively inhibit the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These findings suggest that 5-(methoxymethyl)-1,3-oxazol-4-ylmethanol could be a valuable lead compound for the development of new anti-inflammatory drugs.

The pharmacokinetic properties of 5-(methoxymethyl)-1,3-oxazol-4-ylmethanol have also been extensively studied. Preclinical data indicate that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It has been shown to have good oral bioavailability and a long half-life, which are desirable characteristics for a drug candidate. Furthermore, preliminary toxicology studies have not revealed any significant safety concerns at therapeutic doses.

The synthetic route for producing 5-(methoxymethyl)-1,3-oxazol-4-ylmethanol involves several well-established chemical reactions. One common approach is to start with an appropriate aldehyde or ketone and react it with an amino alcohol to form an intermediate imine or oxime. This intermediate is then cyclized under acidic conditions to form the 1,3-oxazole ring. The methoxymethyl group can be introduced via an alkylation reaction using an appropriate alkylating agent such as methyl iodide or dimethyl sulfate. The final step involves reducing the carbonyl group to form the hydroxymethyl functionality.

In conclusion, 5-(methoxymethyl)-1,3-oxazol-4-ylmethanol (CAS No. 1510076-57-9) is a versatile compound with significant potential in medicinal chemistry. Its unique structural features and favorable pharmacological properties make it an attractive candidate for further research and development. Ongoing studies are expected to uncover additional therapeutic applications and optimize its use in clinical settings.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)